Review of innovative methods of therapy for psoriasis

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This article discusses innovative methods of treating psoriasis, such as 2nd generation Janus kinase (JAK) inhibitors (deucravacitinib), a hydrogel (BVn) based on self-assembling bilirubin nanoparticles and an inhibitor of the amino acid transporter ASCT2 (V9302), a microneedle patch based on hyaluronic acid and two-dimensional inorganic compounds (maxenes), used to introduce monoclonal antibodies (MAbs) directly into the psoriatic lesion, NLRP3 inflammasome inhibitors.

When analyzing modern studies devoted to the evaluation of promising methods for treating psoriasis, two main trends were noted: further research into drugs based on small molecules and the development of new MAbs for more effective and affordable treatment of psoriasis. In addition, current treatment strategies are aimed at relieving symptoms, improving quality of life, and preventing the progression of psoriasis. However, existing methods are limited by side effects, treatment resistance and high costs. These limitations highlight the urgency of searching for new innovative treatment methods.

The uniqueness of this work lies in the fact that it most fully presents the above methods of therapy, and when searching for modern works for analysis, Russian-language articles mainly described new genetically engineered biological drugs (GEBPs), such as interferons, interleukins and Mabs, were used.

全文:

受限制的访问

作者简介

V. Shulepov

Omsk State Medical University

编辑信件的主要联系方式.
Email: shulepov72@icloud.com
ORCID iD: 0009-0005-1984-2309

VI-year Student of the Faculty of Medicine

俄罗斯联邦, Omsk

Yu. Novikov

Omsk State Medical University

Email: shulepov72@icloud.com
ORCID iD: 0000-0003-0391-5372
俄罗斯联邦, Omsk

O. Pravdina

Omsk State Medical University

Email: shulepov72@icloud.com
ORCID iD: 0000-0002-1804-6248
俄罗斯联邦, Omsk

参考

  1. Клинические рекомендации. Псориаз. 2023. Министерство здравоохранения Российской Федерации. [Clinical guidelines. Psoriasis. 2023. Ministry of Health of the Russian Federation. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/234_2.
  2. Griffiths C.E.M., van der Walt J.M., Ashcroft D.M., et al. The global state of psoriasis disease epidemiology: a workshop report. 2017. doi: 10.1111/bjd.15610.
  3. Zarrin, A.A., Bao, K., Lupardus, P., et al. Kinase inhibition in autoimmunity and inflammation. Nature Reviews Drug Discovery. 2021;20(1):39–63. doi: 10.1038/s41573-020-0082-8.
  4. Roskoski Jr R. Deucravacitinb is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642. doi: 10.1016/j.phrs.2022.106642.
  5. Wrobleski S.T., Moslin R., Lin S., et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973–8995. doi: 10.1021/acs.jmedchem.9b00444.
  6. Mullard A. First de novo deuterated drug poised for approval. Nat Rev. Drug Discov. 2022; 21(9):623–25. doi: 10.1038/d41573-02200139-6.
  7. Madison A., Luo Y., Raimondi G., et al. Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies. Pharmaceuticals. 2021;15(1):48. Doi: 10.3390/ ph15010048.
  8. Catlett I.M., Aras U., Hansen L., et al. First‐in-human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023;16(1):151–64. doi: 10.1111/cts.13435.
  9. Xinhui N., Lai Y. Keratinocyte: A trigger or an executor of psoriasis? J Leukoc Biol. 2020;108(2):485–91. doi: 10.1002/JLB.5MR0120-439R.
  10. Jiang X., Huang S., Cai W., et al. Glutamine‐Based Metabolism Normalization and Oxidative Stress Alleviation by Self-Assembled Bilirubin/V9302 Nanoparticles for Psoriasis Treatment. Adv Healthc Mater. 2023;12(13):2203397. doi: 10.1002/adhm.202203397.
  11. Jiang X., Yao Q., Xia X., et al. Self-assembled nanoparticles with bilirubin/JPH203 alleviate imiquimod-induced psoriasis by reducing oxidative stress and suppressing Th17 expansion. Chemical Engineering Journal. 2022;431:133956. Doi: 10.101i6/j.cej.2021.133956.
  12. Keum H., Kim T.W., Kim Y., et al. Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling. J Control Release. 2020;325:359–69. doi: 10.1016/j.jconrel.2020.07.015.
  13. Wang W., et al. Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease. Biol Res. 2019;52(1):49. doi: 10.1186/s40659-019-0255-2.
  14. Scalise M., Pochini L., Console L., et al. The human SLC1A5 (ASCT2) amino acid transporter: from function to structure and role in cell biology. Front Cell Dev Biol. 2018;6:96. doi: 10.3389/fcell.2018.00096.
  15. Bullock J.L., Gillette D.D., Smith J.A. Small molecule, nanoparticle and liposomal strategies for LAT1-mediated chemotherapy delivery. Results Chem. 2023;6:101056. doi: 10.1016/j.rechem.2023.101056.
  16. Patel A.B., Tsilioni I., Weng Z., et al. TNF stimulates IL-6, CXCL 8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. Exp Dermatol. 2018;27(2):135–43. doi: 10.1111/exd.13461.
  17. Sun L., Liu Z., Wang L., et al. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release. 2017;254:44–54. doi: 10.1016/j.jconrel.2017.03.385.
  18. Bigliardi P.L. Role of skin pH in psoriasis. Curr Probl Dermatol. 2018;54:108–14. doi: 10.1159/000489524.
  19. Orsmond A., Bereza-Malcolm L., Lynch T., et al. Skin barrier dysregulation in psoriasis. Int J Molecular Sci. 2021;22(19):10841. doi: 10.3390/ijms221910841.
  20. Wu D., Shou X., Yu Y., et al. Biologics‐Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment. Adv Functional Mater. 2022;32(47):2205847. doi: 10.1002/adfm.202205847.
  21. Iravani S., Varma R. S. MXenes in photomedicine: Advances and prospects. Chem Commun (Camb). 2022;58(53):7336–7350. doi: 10.1039/D2CC01694J.
  22. Li H., Fan R., Zou B., et al. Roles of MXenes in biomedical applications: recent developments and prospects. J Nanobiotechnol. 2023;21(1):1–39. doi: 10.1186/s12951-023-01809-2.
  23. Jiang L., Zhou D., Yang J., et al. 2D single-and few-layered MXenes: synthesis, applications and perspectives. J Mater Chem A. 2022;10(26):13651–72. doi: 10.1039/D2TA01572B.
  24. Dai Y., Zhou J., Shi C. Inflammasome: structure, biological functions, and therapeutic targets. Med Comm. 2023;4(5):e391. doi: 10.1002/mco2.391.

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Cytokine signaling through the JAK-STAT pathway [4]

下载 (598KB)
索引源数据
3. Figure 2. Structure of JAK inhibitors [4]

下载 (666KB)
索引源数据
4. Figure 3. Schematic representation of the application of a photo-thermosensitive patch with MAT for the treatment of psoriasis [20]

下载 (700KB)
索引源数据
5. Figure 4. Structure of the NLRP3 inflammasome [24]

下载 (523KB)
索引源数据
6. Figure 5. Overview of the process of NLRP3 inflammasome formation and activation [24]

下载 (1MB)
索引源数据

版权所有 © Bionika Media, 2024